/EKSO
EKSO Stock - Ekso Bionics Holdings, Inc.
Healthcare|Medical - Instruments & SuppliesNASDAQ
$4.86+0.83%
+$0.04 (+0.83%) • Dec 19
76
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.57
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).97
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.87
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+23.5%upside
Target: $6.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for EKSO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.81 – $4.91
TARGET (TP)$6.00
STOP LOSS$4.47
RISK/REWARD1:2.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.82
52W High$14.97
52W Low$2.73
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $17.93M | $18.28M | $12.91M | $11.25M | $8.88M |
| Gross Profit | $9.51M | $9.08M | $6.21M | $6.75M | $5.07M |
| Gross Margin | 53.1% | 49.7% | 48.1% | 60.0% | 57.1% |
| Operating Income | $-10,460,000 | $-15,112,000 | $-15,556,000 | $-13,828,000 | $-12,858,000 |
| Net Income | $-11,330,000 | $-15,198,000 | $-15,080,000 | $-9,764,000 | $-15,825,000 |
| Net Margin | -63.2% | -83.1% | -116.8% | -86.8% | -178.2% |
| EPS | $-0.56 | $-1.10 | $-1.16 | $-0.80 | $-2.21 |
Company Overview
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
EKSOBeat Rate
32%
Last 19 quarters
Avg Surprise
-14.0%
EPS vs Estimate
Beats / Misses
6/13
Last 12 quarters
Latest EPS
$-0.54
Q4 2025
EPS Surprise History
Q1 24
-100.0%
$-0.22vs$-0.11
Q2 24
-25.0%
$-0.20vs$-0.16
Q3 24
-18.2%
$-0.13vs$-0.11
Q4 24
-25.0%
$-0.10vs$-0.08
Q1 25
-100.0%
$-0.14vs$-0.07
Q2 25
-9.1%
$-1.80vs$-1.65
Q3 25
-3.3%
$-1.24vs$-1.20
Q4 25
+45.5%
$-0.54vs$-0.99
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 2, 2026 | $-0.21 | — | — | — |
Q4 2025 | Oct 28, 2025 | $-0.99 | $-0.54 | +45.5% | ✓ BEAT |
Q3 2025 | Jul 28, 2025 | $-1.20 | $-1.24 | -3.3% | ✗ MISS |
Q2 2025 | May 5, 2025 | $-1.65 | $-1.80 | -9.1% | ✗ MISS |
Q1 2025 | Mar 3, 2025 | $-0.07 | $-0.14 | -100.0% | ✗ MISS |
Q4 2024 | Oct 28, 2024 | $-0.08 | $-0.10 | -25.0% | ✗ MISS |
Q3 2024 | Jul 29, 2024 | $-0.11 | $-0.13 | -18.2% | ✗ MISS |
Q2 2024 | Apr 29, 2024 | $-0.16 | $-0.20 | -25.0% | ✗ MISS |
Q1 2024 | Mar 4, 2024 | $-0.11 | $-0.22 | -100.0% | ✗ MISS |
Q4 2023 | Oct 26, 2023 | $-0.31 | $-0.24 | +22.6% | ✓ BEAT |
Q3 2023 | Jul 27, 2023 | $-0.28 | $-0.31 | -10.7% | ✗ MISS |
Q2 2023 | Apr 27, 2023 | $-0.31 | $-0.33 | -6.5% | ✗ MISS |
Q1 2023 | Mar 28, 2023 | $-0.22 | $-0.24 | -9.1% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.24 | $-0.33 | -37.5% | ✗ MISS |
Q3 2022 | Jul 28, 2022 | $-0.24 | $-0.23 | +4.2% | ✓ BEAT |
Q2 2022 | Apr 28, 2022 | $-0.41 | $-0.36 | +12.2% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-0.25 | $-0.23 | +8.0% | ✓ BEAT |
Q4 2021 | Nov 2, 2021 | $-0.25 | $-0.17 | +32.0% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $-0.25 | $-0.26 | -4.0% | ✗ MISS |
Q2 2021 | Apr 29, 2021 | $-0.24 | $-0.34 | -41.7% | ✗ MISS |
Latest News
Ekso Bionics Enters Into Agreement With MediTouch To Become Exclusive Authorized Sales Agent And Distributor Of MediTouch's BalanceTutor Rehabilitation System In US
📈 PositiveBenzinga•Dec 4, 2025, 12:47 PM
HC Wainwright & Co. Maintains Buy on Ekso Bionics Holdings, Raises Price Target to $6
📈 PositiveBenzinga•Nov 18, 2025, 03:42 PM
EKSO stock has given up its prior loss. Ekso Bionics shares were trading lower after the company announced a $3.7 million registered direct offering of 769,490 shares at a purchase price of $4.81 per share.
➖ NeutralBenzinga•Oct 29, 2025, 01:21 PM
Ekso Bionics shares are trading lower after the company announced a $3.7 million registered direct offering of 769,490 shares at a purchase price of $4.81 per share.
📉 NegativeBenzinga•Oct 29, 2025, 12:01 PM
Ekso Bionics Announces $3.7M Registered Direct Offering Of 769,490 Shares At Purchase Price Of $4.81/Share
➖ NeutralBenzinga•Oct 29, 2025, 12:01 PM
Ekso Bionics Says Is In Process Of Exploring One Or More Strategic Transactions With Certain Third Parties; Transactions May Include Acquisition Of Line Of Business And/or Sale Of All Or Substantially All Of Co's Current Business
➖ NeutralBenzinga•Oct 28, 2025, 09:12 PM
Ekso Bionics Holdings Q3 EPS $(0.54) Beats $(1.15) Estimate, Sales $4.227M Miss $4.346M Estimate
➖ NeutralBenzinga•Oct 28, 2025, 08:44 PM
Ekso Bionics Secures $2M Term Loan From B. Riley At 10% Interest, Matures September 14, 2026
📈 PositiveBenzinga•Sep 17, 2025, 08:11 PM
Frequently Asked Questions about EKSO
What is EKSO's current stock price?
Ekso Bionics Holdings, Inc. (EKSO) is currently trading at $4.86 per share. The stock has moved +0.83% today.
What is the analyst price target for EKSO?
The average analyst price target for EKSO is $6.00, based on 1 analyst.
What sector is Ekso Bionics Holdings, Inc. in?
Ekso Bionics Holdings, Inc. operates in the Healthcare sector, specifically within the Medical - Instruments & Supplies industry. The company is traded on the NASDAQ exchange.
What is EKSO's market cap?
Ekso Bionics Holdings, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does EKSO pay dividends?
No, Ekso Bionics Holdings, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAEMD
Aethlon Medical, Inc.
$2.86
Mkt Cap: $0.0B
ALUR
Allurion Technologies Inc.
$1.47
Mkt Cap: $0.0B
ANL
Adlai Nortye Ltd.
$1.52
Mkt Cap: $0.0B
AYTU
Aytu BioPharma, Inc.
$2.55
Mkt Cap: $0.0B
CODX
Co-Diagnostics, Inc.
$0.26
Mkt Cap: $0.0B
ERNA
Ernexa Therapeutics Inc.
$1.31
Mkt Cap: $0.0B
GOVX
GeoVax Labs, Inc.
$0.16
Mkt Cap: $0.0B
NVNO
enVVeno Medical Corporation
$0.32
Mkt Cap: $0.0B
OSRH
OSR Holdings, Inc.
$0.65
Mkt Cap: $0.0B
PRPH
ProPhase Labs, Inc.
$0.09
Mkt Cap: $0.0B
Explore stocks similar to EKSO for comparison